SpyGlass Pharma, Inc.

SGP·NasdaqGS
Compare
24.86−0.06 (−0.24%)today
At close: Oct 12, 4:00 PM EDT · May be delayed up to 15 min · USD
After hours24.860.00 (0.00%)Oct 12, 4:00 PM EDT

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close24.92
Open24.60
Day range24.1425.54
52-week range17.0632.44
Off day high−2.66%
Off 52-week high−23.37%
Volume59.47K
Avg. volume (3M)108.42K
Market cap831.52M
EPS (TTM)-2.51
Forward P/E-8.83
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)—
Shares outstanding33.45M
Short interest—
Earnings dateNov 5, 2026 (est.)
Analyst target—
Profit margin—

Against its peers

Compare in full ›
SGP YDES OCUL EYPT ARDX OCS
Market cap 831.52M 448.36M 1.66B 278.35M 833.95M 485.31M
P/E (TTM) — — — — — —
Forward P/E -8.8 — -5.1 -1.2 11.1 -4.1
Price/book 3.6 1.4 3.2 1.7 5.4 1.9
Dividend yield — — — — — —
1-year change −5.61% −63.54% −36.37% −74.51% −35.53% −60.29%
Today −0.24% −5.94% +0.27% −2.35% −1.52% −5.52%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Latest news

All SGP news ›
Eyes On Eyecare·Positive

SpyGlass Pharma unveils positive 12-month data on BIM-IOL System

Interim 12-month safety and efficacy data on SpyGlass Pharma’s bimatoprost drug pad-intraocular lens system (BIM-IOL System) were presented over the weekend during the American Academy of Ophthalmology (AAO) annual meeting in New Orleans,…

markets.businessinsider.com·Positive

SpyGlass Pharma to Participate in Upcoming Investor Conferences

IRVINE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the executive management team will participate…

markets.businessinsider.com·Positive

SpyGlass Pharma acquires Advanced Vision Science for $13M in cash

SpyGlass Pharma (SGP) announced the acquisition of all the outstanding shares of common stock of Advanced Vision Science for approximately $13M ... SpyGlass Pharma acquires Advanced Vision Science for $13M in cash SpyGlass Pharma (SGP)…

markets.businessinsider.com·

Stifel Nicolaus Sticks to Its Buy Rating for SpyGlass Pharma (SGP)

Stifel Nicolaus analyst Thomas Stephan maintained a Buy rating on SpyGlass Pharma today and set a price target of $42.00. According to TipRanks, Stephan is a 4-star analyst with an average return of 10.4% and a 46.08% success rate. Stephan…

markets.businessinsider.com·Positive

SpyGlass Pharma initiated with an Outperform at Raymond James

Raymond James analyst Christopher Raymond initiated coverage of SpyGlass Pharma (SGP) with an Outperform rating and $39 price target SpyGlass P... SpyGlass Pharma initiated with an Outperform at Raymond James Raymond James analyst…

MarketScreener·

SpyGlass Pharma, Inc. : Insider Transactions

Follow insider transactions on SpyGlass Pharma, Inc. in real time. Filter by importance or transaction type and analyze the history on MarketScreener. Insider Transactions SpyGlass Pharma, Inc. Medical Equipment, Supplies & Distribution…

MarketScreener·

SpyGlass Pharma, Inc.: Official Announcements - Stock Market News

Find the latest press releases and official documents published by SpyGlass Pharma, Inc. on MarketScreener. Press Releases SpyGlass Pharma, Inc. Medical Equipment, Supplies & Distribution All financial news and data tailored to specific…

MarketScreener·Positive

SpyGlass Pharma, Inc.: Latest Headlines - Nasdaq Stock Exchange

Find the latest highlights on SpyGlass Pharma, Inc. at the Nasdaq stock exchange. Highlights SpyGlass Pharma, Inc. Medical Equipment, Supplies & Distribution All financial news and data tailored to specific country editions

From articles in the 4Search news index.

In the news

35mentions in 30 days
26with it in the headline
Positivesentiment

Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 35 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Conservative index. Terms of use.